According to related industries, AstraZeneca Korea and Ildong Pharmaceutical have decided to jointly promote Qtern, which combines DPP-4 inhibitor Onglyza (Saxagliptin) and SGLT-2 inhibitor Forxiga(Dapagliflozin), which will be released today (1st).

Since March 2014, the two companies have already been conducting co-marketing on diabetes treatments such as Onglyza and Kombiglyze XR(Metformin·Saxagliptin).

Qtern jointly conducts sales and marketing of the product at general hospitals and Ildong Pharmaceutical alone at clinics. With the official launch of Qtern, the market for diabetes combination drugs is expected to change.

Currently, in addition to Qtern, combinations of